Interview with Stephen Turley, Managing Director, Lundbeck Limited (UK)
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
Address: Lundbeck House, Caldecotte Lake Drive, Caldecotte Lake, , Milton Keynes, MK7 8LG, United Kingdom
,United Kingdom
Tel: 0044 1908 649 966
Web: http://uk.lundbeck.com/uk/
Lundbeck is one of Denmark’s most research-intensive enterprises. We employ a total of 1,200 highly-trained specialists in our research and development units. Each year, Lundbeck ploughs back more than 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from neurological disorders.
Lundbeck UK are specialists in psychiatry and pioneers in neurology. We are an international pharmaceutical organisation with a head office based in Milton Keynes, UK and a national field force. The office consists of; Sales & Marketing, Finance & Administration, Human Resources, Medical, and Business Intelligence.
Specialists in psychiatry, pioneers in neurology
As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmaceuticals for psychiatric and neurological disorders, and are pioneers of new treatments and new approaches.
As specialists, our research and development is focused and concentrated. As specialists, we maintain close ties to our customers, establishing new links, building knowledge and developing new programmes. And as specialists, we are closer to the people suffering from psychiatric disorders and the people treating them.
UK Brand Name UK Generic Name
Azilect 1mg Tablets rasagiline
Circadin 2mg prolonged-release tablets melatonin
Cipralex 5mg/10mg/20mg Tablets escitalopram
Cipralex 10mg/ml Drops escitalopram
Cipramil 40mg/ml Drops citalopram
Cipramil 10mg/20mg/40mg Tablets citalopram
Clopixol Acuphase Injection zuclopenthixol
Clopixol Conc Injection zuclopenthixol
Clopixol Injection zuclopenthixol
Clopixol 2mg/10mg/25mg Tablets zuclopenthixol
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave…
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational…
Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing…
A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status…
The Window Conference Center is hosting at least six pharmaceutical events within a month, and has a broad prior history of orchestrating such occasions. How important is the pharmaceutical industry…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
You joined Apodi in 2008, after a hiatus from the industry following the sale of your previous company, In2Focus, in 2007. What has been the most challenging aspect of your…
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
See our Cookie Privacy Policy Here
